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Background: Epidermal growth factor receptor is overexpressed in most pediatric high-
grade gliomas (HGG). Since erlotinib had shown activity in adults with HGG, we conducted
a phase II trial of erlotinib and local radiotherapy (RT) in children with newly diagnosed HGG.
Methods: Following maximum surgical resection, patients between 3 and 21 years with
non-metastatic HGG received local RT at 59.4 Gy (54 Gy for spinal tumors and those
with ≥70% brain involvement). Erlotinib started on day 1 of RT (120 mg/m2 per day) and
continued for 2 years unless there was tumor progression or intolerable toxicities. The 2-
year progression-free survival (PFS) was estimated for patients with intracranial anaplastic
astrocytoma (AA) and glioblastoma (GBM).
Results: Median age at diagnosis for 41 patients with intracranial tumors (21 with GBM
and 20 with AA) was 10.9 years (range, 3.3–19 years). The 2-year PFS for patients with AA
and GBM was 15±7 and 19±8%, respectively. Only five patients remained alive without
tumor progression. Twenty-six patients had at least one grade 3 or 4 toxicity irrespec-
tive of association with erlotinib; only four required dose modifications.The main toxicities
were gastrointestinal (n=11), dermatologic (n= 5), and metabolic (n=4). One patient with
gliomatosis cerebri who required prolonged corticosteroids died of septic shock associated
with pancreatitis.
Conclusion: Although therapy with erlotinib was mostly well-tolerated, it did not change
the poor outcome of our patients. Our results showed that erlotinib is not a promising
medication in the treatment of children with intracranial AA and GBM.
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INTRODUCTION
High-grade gliomas (HGGs) arising outside the brainstem
account for 8–12% of all pediatric central nervous system tumors
(1). The 5-year survival for children with glioblastoma (GBM) and
anaplastic astrocytoma (AA), the most common types of HGGs,
remains <15 and <30%, respectively, despite the use of multi-
modality therapies consisting of maximum surgical resection,
radiotherapy (RT), and different regimens of chemotherapy (2–4).
The epidermal growth factor receptor (EGFR) belongs to a
family of cell-surface proteins that also includes human epidermal
growth factor receptors (HER) 2–4. EGFR is activated by binding
to its ligands, leading to autophosphorylation of its intracellular
tyrosine kinase domain (5). This autophosphorylation activates a
downstream cascade of proteins involved in various cell-survival
functions. Activation of EGFR is important for tumor survival and
growth and is associated with poor clinical outcome in different
malignancies (5).
Several EGFR inhibitors have been used for treating differ-
ent types of cancers, including GBM (5–7). Erlotinib (Tarceva™,
OSI Pharmaceuticals, Melville, NY, USA; Roche, Basel, Switzer-
land; and Genentech, South San Francisco, CA, USA) is an orally
active, potent, and selective inhibitor of EGFR and HER2 (8). Early
studies showed that EGFR amplification is rare in pediatric HGG
(9, 10). However, EGFR is overexpressed by immunohistochem-
istry in 80% of these tumors (11). Preliminary studies showed
promising activity of erlotinib against GBM in adult patients (12,
13). In a phase I study of adults with malignant gliomas receiv-
ing erlotinib alone or with temozolomide, eight [GBM (n= 5), AA
(n= 1), gemistocytic astrocytoma (n= 1), and oligodendroglioma
(n= 1)] of 57 evaluable patients had a partial response, six of
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whom received only erlotinib (12). Of these eight patients, four
had a progression-free survival (PFS) of more than 6 months,
including three patients with GBM. Also, two patients [GBM
(n= 1) and AA (n= 1)] with no tumor response to therapy had
a PFS of ≥6 months, including one patient who received only
erlotinib.
The preliminary results of clinical trials in adults and the high
incidence of EGFR overexpression in pediatric HGGs provided
the rationale for conducting a pediatric study using erlotinib
to treat children with HGG. Our institution completed a phase
I clinical trial, including pharmacokinetic studies, of erlotinib
administered during and after RT in children with HGG (14).
There were 23 children (12 GBM, 8 AA, and 3 other HGG) treated
on our phase I study. The maximum tolerated dose (MTD) of
erlotinib was 120 mg/m2 per day. Dose limiting toxicities (DLT)
in our phase I study were grade 3 diarrhea despite supportive
care (n= 1 at MTD level), grade 3 increase in serum lipase con-
comitant with abdominal pain, and grade 3 intolerable skin rash
associated with pruritus. The latter two DLT occurred at dose
level of 160 mg/m2 per day. Use of erlotinib for at least 6 months
(n= 18) and 12 months (n= 12) was well-tolerated with chronic
toxicities such as grade 1–3 indirect hyperbilirubinemia, grade 1–3
hypokalemia and hypophosphatemia, and grade 1–3 lymphope-
nia. Also, one of our patients on the phase I study developed a
second neoplasm (rhabdomyosarcoma) outside the radiation field
within 6 months of therapy.
We present the results of the phase II study combining RT and
erlotinib in children with newly diagnosed, intracranial GBM and
AA. Although the outcomes of our patients were not better than
those reported in previous clinical trials, our results are relevant
since EGFR-targeting agents alone or in combination, particularly
erlotinib, continue to be tested in several recent clinical trials on
pediatric HGG.
PATIENTS AND METHODS
Patients aged 3–21 years with non-metastatic, newly diagnosed
HGG or unfavorable low-grade glioma were eligible for this phase
II trial (NCT00124657). Unfavorable low-grade gliomas were
defined as World Health Organization grade II gliomas with the
radiologic diagnosis of gliomatosis cerebri or bithalamic involve-
ment. However, only data from patients with intracranial GBM or
AA were included in the analysis of PFS and overall survival (OS).
Except for one case, all tumors were centrally reviewed at St. Jude
Children’s Research Hospital (St. Jude). Five patients (four with
GBM and one with AA) were previously treated at the MTD dur-
ing the phase I study (14); these patients met the eligibility criteria
for the phase II study and were included in this analysis.
Additional eligibility criteria included an interval of ≤42 days
between surgery and start of therapy; a performance score≥40 and
adequate organ functions (absolute neutrophil count ≥1000/µL,
platelet count ≥100,000/µL, hemoglobin concentration ≥8 g/dL,
serum creatinine concentration less than twice the institutional
normal values for age, total bilirubin <1.5 times the upper limit
of normal, alanine aminotransferase <5 times the institutional
upper limit of normal, and albumin ≥2g/dL). Exclusion criteria
included diagnosis of diffuse intrinsic pontine glioma, diagnosis of
radiation induced HGG, use of enzyme-inducing anticonvulsants,
use of other concomitant anticancer treatments, presence of other
significant medical problems, and pregnancy or lactation.
The institutional review boards (IRBs) at St. Jude and Rady
Children’s Hospital approved the study before initial patient
enrollment, and a written informed consent (or assent when
appropriate) was obtained from patients or their legal guardians.
STUDY DESIGN AND TREATMENT PLAN
Patients from St. Jude and Rady Children’s Hospital were enrolled
on the study. Following maximum surgical resection, eligible
patients received 59.4 Gy local RT administered at a dose of 1.8 Gy
per fraction, 5 days per week for 6.5 weeks. The treatment volume
encompassed the entire tumor defined on preoperative imaging
by the combination of T1, T2-weighted, and FLAIR sequences,
a 2-cm margin to account for microscopic disease, and a 0.3- to
0.5-cm margin to account for uncertainty in immobilization and
patients’ positioning. The prescribed RT dose was limited to 54 Gy
when the required target volume included ≥70% of the whole
brain and in patients with spinal tumors.
Since the degree of surgical resection is a major prognostic
factor for children with HGG (2), achieving a gross or near-total
resection was attempted whenever possible even if more than one
surgical procedure was required. Gross total resection was defined
as no visible tumor left based on imaging and operative report, and
near-total resection was identified as removal of>90% but<100%
of the tumor. Subtotal and partial resections were defined as resec-
tion of 50–89 and 10–49% of the tumor, respectively. Biopsies were
defined as <10% of tumor resection.
Erlotinib was initiated on the first day of RT at the phase
II recommended dose of 120 mg/m2 per day (maximum dose
200 mg per day) (14). Patients received erlotinib for 26 courses
(2 years) without interruption unless there was tumor progression
or intolerable toxicities. Each course of erlotinib lasted 28 days.
Table 1 provides the recommendations for dose modifications
in case of significant toxicities. All adverse events were graded
according to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 3.0. Clinical and
radiologic evaluations were similar to those used in the phase I
trial (14).
Progression-free survival was defined as the interval between
the start of treatment and initial failure, including clinical or radi-
ologic progression, or death from any cause. OS was defined as
the interval between the start of treatment and death. Progres-
sive disease (PD) was defined as worsening neurologic status not
explained by causes unrelated to tumor progression, or a greater
than 25% increase in the product of the maximum perpendicu-
lar diameters of any lesions, or increasing doses of corticosteroids
required to maintain stable neurologic status.
STATISTICAL CONSIDERATIONS
The primary objective of the current trial was to estimate the PFS
for patients with intracranial AA and GBM by the Kaplan–Meier
method. The “intent-to-treat” principle was followed, and all eli-
gible patients who received any treatment were included in the
analyses. The sequential probability ratio test (SPRT) was used
to monitor PFS independently for patients with AA and GBM in
order to halt accrual within each stratum as soon as statistical
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Table 1 | Recommended dose modifications in the phase II study.
Toxicity Action at first occurrence Action at recurrence Grounds for drug discontinuation
Non-hematologic grade 2
(except skin rash and
diarrhea)a
Hold erlotinib until resolution to ≤grade
1; restart at 90 mg/m2 per day
If grade 2, hold erlotinib until resolution
to ≤grade 1; restart at 70 mg/m2 per
day
If recurrent grade 2 toxicity after
two dose reductions
Diarrhea and/or skin rash
grade 2
Supportive care only; hold erlotinib and
restart at 90 mg/m2 per day if duration
>7 days and toxicity intolerable
Supportive care only; hold erlotinib and
restart at 70 mg/m2 per day if duration
>7 days and toxicity intolerable
If recurrent grade 2 intolerable
toxicity lasting >7 days after 2 dose
reductions
Non-hematologic grade 3b Hold erlotinib until resolution to ≤grade
2; restart erlotinib at 90 mg/m2 per day if
resolution ≤7 days. Discontinue erlotinib
if grade 3 toxicity persists for >7 days
Discontinue erlotinib if recurrent grade
3 toxicity occurs after 1 dose reduction
If grade 3 toxicity lasts >7 days or if
grade 3 toxicity recurs after one
dose reduction
Transaminase grade 3
(lasting >7 days)
Hold erlotinib until resolution to ≤grade
1; resume at 90 mg/m2 per day
Discontinue erlotinib if recurrent grade
3 toxicity lasts >7 days
If recurrent grade 3 toxicity lasts
>7 days
Non-hematologic grade 4c Discontinue erlotinib
Interstitial lung disease If suspected, hold erlotinib until disease
is ruled out or improved
Since hematologic toxicities were not expected with erlotinib, the protocol mandated that the PI to be contacted for grade 3 and 4 hematologic toxicities, prior any
holding of modifying the erlotinib dose.
aNot attributable to another cause and severe enough to warrant treatment discontinuation.
bExcluding weight gain or loss, diarrhea for ≤48 h not given optimal supportive therapy, tolerable skin rash, fever or non-neutropenic infection, nausea, and vomiting
for ≤48 h not given optimal supportive therapy, seizures, elevation of transaminases that resolves to ≤grade 1 within 7 days of discontinuing the drug, or electrolyte
abnormalities that resolve to ≤grade 2 within 7 days with or without clinical intervention.
cExcluding grade 4 electrolyte abnormalities that resolve to ≤grade 2 within 7 days with or without clinical intervention.
confidence developed that the treatment regimen was not meeting
efficacy expectations (15). The SPRT monitoring design for each
stratum was based on type 1 and type 2 error rates of 0.10, and
monitoring did not begin until five failures had been observed. The
fully sequential monitoring rule for patients with AA was based
on comparing true and unknown 2-year PFS rates of 25 versus
45%, respectively. The monitoring criteria for patients with GBM
were based on comparing true and unknown 2-year PFS rates of
10 versus 25%, respectively. The maximum expected accrual was
29 patients with AA and 30 with GBM. Futility analyses closed
accrual for patients with AA and GBM after the 14th and 16th fail-
ures, respectively. At that point, 20 patients with AA and 21 with
GBM had been accrued to this study. The Fisher’s exact test was
used to examine the correlation between dexamethasone use and
lymphopenia.
RESULTS
PATIENTS’ CHARACTERISTICS
Thirty-nine patients were enrolled on the phase II study between
August 2007 and November 2010. Five additional patients treated
at the MTD during the phase I trial were incorporated into
the current analysis (14). Overall, 20 patients had AA, 21 had
GBM, one had anaplastic oligoastrocytoma, one had unfavor-
able fibrillary astrocytoma, and one had spinal GBM. All patients
underwent complete imaging evaluation of the neuraxis before the
start of therapy, which showed no evidence of metastatic disease.
All 44 patients were included for evaluation of toxicity profiles.
Forty-three patients were treated at St. Jude and one at Rady
Children’s Hospital.
Table 2 provides the characteristics of 41 patients with intracra-
nial AA and GBM who were eligible for PFS estimation. Thirteen
(32%) of these 41 patients had gliomatosis cerebri (n= 7; five with
AA and two with GBM) or bithalamic tumors (n= 6; five with AA
and one with GBM).
OUTCOMES
After excluding the three non-intracranial GBM or AA cases (one
anaplastic oligoastrocytoma, one unfavorable fibrillary astrocy-
toma, and one spinal GBM), the 2-year PFS was 15± 7 and
19± 8% for patients with intracranial AA and GBM, respectively
(Figure 1). The 2-year OS for patients with AA and GBM was
20± 8 and 19± 8%, respectively. The 5-year PFS was 15± 8 and
9.5± 9% for patients with AA and GBM, respectively. The 5-year
OS for patients with AA and GBM was 15± 10 and 14± 13%,
respectively. The median PFS for patients with AA and for GBM
was 10.7 and 6.3 months, respectively. The median OS for patients
with AA and GBM was 15.4 and 11.7 months, respectively.
Two patients died while on study, one each from disease pro-
gression and toxicity. The median follow-up for these 41 patients
was 13.5 months (range, 1.8–66.5 months).
Thirty-five of 41 patients died (17 AA, 18 GBM), all except
one due to disease progression. Five patients (three with AA, two
with GBM) remain alive without experiencing disease progres-
sion. The median duration of follow-up for these five patients was
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Table 2 | Patients’ characteristics.
Characteristic All patients (n=41) AA (n=20) GBM (n=21)
AGE AT DIAGNOSIS (YEARS)
Median 10.9 11.8 8.9
Range 3.3–19 3.6–19 3.3–16.6
LENGTH OF FOLLOW-UP (MONTHS)a
Median 13.5 16.0 11.7
Range 1.8–66.5 3.9–66.5 1.8–54.8
SEX
Female 24 11 13
Male 17 9 8
RACE
White 30 15 15
Black 7 4 3
Other 4 1 3
ETHNICITY
Non-Hispanic 37 18 19
Hispanic 4b 2 2
LOCATION
Cerebrum 22 10 12
Cerebellum 5 1 4
Thalamus 13 9 4
Pineal 1 0 1
EXTENT OF RESECTION
Gross/near-total 10 4 6
Subtotal 12 3 9
Partial/biopsy 19 13 6
AA, anaplastic astrocytoma; GBM, glioblastoma multiforme.
aDefined as last contact.
bIncluded one of each of the following: Cuban, Mexican, Central/South American,
and Spanish not other was specified.
55 months (range, 43–66.5 months), of whom three underwent a
gross total resection (two with AA and one with GBM), one a
subtotal resection (AA), and one a biopsy only (GBM). Two of
these five patients discontinued erlotinib due to non-compliance
after less than 1 and 12 courses of therapy, respectively. One patient
with intracranial GBM who remains alive experienced disease
progression 54 months after diagnosis.
PROGRESSIVE DISEASE CHARACTERISTICS
Of 35 patients who developed PD, 25 had local progression only,
five experienced metastatic failures (three in the spine and two in
distant locations within the brain), and five had both local and
metastatic PD. Metastatic disease in patients with mixed PD was
ventricular (n= 3), spinal (n= 1), and cerebellar (n= 1).
TOXICITIES
Twenty-six (59%) of 44 patients developed at least one grade 3 or 4
toxicity irrespective of attribution to erlotinib. Patients received a
median of nine courses of chemotherapy (range 1–33). One of the
five patients enrolled on the phase I study received 33 courses of
chemotherapy since treatment duration was extended for 3 years in
the phase I trial (14). The dose of erlotinib was reduced six times in
four patients (dose reduction required twice in two patients) due to
grade 3 or 4 non-hematologic toxicities (gastrointestinal and der-
matologic in three instances each). Treatment with erlotinib was
discontinued because of PD (n= 32), non-compliance (n= 4),
or toxicity (n= 1). The four non-compliant patients received less
than one course (n= 1), six courses (n= 2), and 12 courses (n= 1)
of erlotinib. Seven patients tolerated erlotinib well and completed
the planned therapy. Table 3 summarizes the toxicities in patients.
The only treatment-related mortality occurred in a 12.9-year-
old African-American female with extensive gliomatosis cerebri
(AA) who was on chronic use of corticosteroids for 44 weeks
FIGURE 1 |Two-year progression-free survival curves for patients with glioblastoma and anaplastic astrocytoma.
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Table 3 |Toxicity profiles of the study cohort irrespective of attribution
to erlotinib.
Category Toxicity
description
Toxicity grade Distinct patients
for each category
Grade 3 Grade 4
Blood Hemoglobin 2 1 18
Lymphopeniaa 7 9
Neutrophils 2 1
Platelets – 1
Dermatologic Pruritus 3 – 5
Rash/
desquamation
1 –
Rash/acne 2 –
Gastrointestinal Anorexia 3 – 11
Diarrhea 5 –
Dysphagia 1 –
Mucositis 1 –
Nausea 2 –
Vomiting 4 –
Metabolic ALT/AST 2 – 4
Hypokalemia 2 –
Bilirubin 1 –
Painb Headache 1 1 2
Constitutional Fatigue 1 – 3
Weight loss 2 –
Total distinct number of patients 26
aEight of the 16 patients with lymphopenia received dexamethasone within
4 weeks of the recorded toxicity.
bThere was a documented progressive disease within 3 days of the recorded
headache.
(30 weeks before study enrollment). Erlotinib was held in this
patient after 73 days of treatment because of diarrhea. Three days
later, laboratory tests and imaging confirmed pancreatitis. Peak
serum levels of lipase and amylase were 892 units/L (grade 4 tox-
icity) and 375 units/L (grade 3 toxicity), respectively. Her lowest
total and ionized calcium concentrations were 6.9 and 1.1 mmol/L,
respectively. Her peak total and direct bilirubin concentrations
were 8.9 and 6.2 mg/dL, respectively. She also developed a wound
infection at the craniotomy site. She subsequently developed septic
shock and died 99 days after the start of therapy. An autopsy was
not performed. It was impossible to determine the exact cause of
the septic shock in this patient, but we believe that the pancreatitis
was the main contributing factor.
DISCUSSION
Unlike for adults with HGG (16), no chemotherapy regimen is
considered part of standard care for children with newly diagnosed
HGG in North America. When our phase II trial was designed,
temozolomide during and/or after local RT did not improve the
outcome of children with AA and GBM (3, 4). The failure of
temozolomide to improve the outcome of children with HGG,
the common overexpression of EGFR in pediatric HGG, and the
preliminary promising activity of erlotinib against recurrent GBM
in adults prompted us to conduct this trial (3, 4, 11–13).
We showed that the use of erlotinib during and after RT did
not improve the poor outcome of children with newly diagnosed
intracranial AA and GBM. Although five patients were long-
term survivors and free of tumor progression, including one who
received less than 1 course of erlotinib, the majority had at least
one characteristic at diagnosis associated with a better outcome
(e.g., the diagnosis of AA and the presence of no residual disease
at the start of therapy). On the other hand, a large majority of our
41 patients had poor prognostic factors before the start of ther-
apy, including less than a gross total/near-total resection (76%),
presence of gliomatosis cerebri (17%), or tumors arising from one
(17%) or both thalami (15%) (17, 18). Interestingly, the majority
of the gliomatosis cerebri cases (5 of 7) and bithalamic tumors (5
of 6) were patients with AA tumors, and this could explain the
similar outcome to GBM patients in our cohort.
Three phase I trials reported the safety, pharmacokinetics, and
MTD of erlotinib alone or in combination in children with newly
diagnosed or progressive/recurrent brain and solid tumors (14,
19, 20). In one study, two patients, one with a malignant glioma
and one with an anaplastic oligoastrocytoma, experienced a 44
and 47% tumor regression after therapy with erlotinib alone,
respectively (20).
Similar to our phase I trial (14), we incorporated detailed,
optional plasma pharmacokinetic analysis in the current study.
Unfortunately, adherence to these studies was very low in the phase
II trial, which precluded any meaningful analysis.
Erlotinib was in general well-tolerated by our patients. Only
four (9%) patients required dose modification due to toxicities,
specifically significant diarrhea and skin rash. Other grade 3 and
4 toxicities were uncommon and were mainly pruritus, anorexia
with weight loss, nausea, and vomiting, indirect hyperbilirubine-
mia, increase in liver function tests, and hypokalemia. These tox-
icities were very similar to those described in both phase II adult
and phase I pediatric trials using erlotinib as a single agent (14,
19–22). To explain the high rate of lymphopenia in our study, we
examined the correlation between the use of dexamethasone and
onset of lymphopenia. One patient who was treated outside of St.
Jude was not included in the analysis due to lack of dexamethasone
information. There were 16 patients who had at least one episode
of grade 3/4 lymphopenia in this study. Eight of them (8/16, 50%)
received dexamethasone as concomitant treatment. Among the
other 27 patients, 9 of them (9/27, 33%) received dexamethasone.
The Fisher’s exact test has p-value= 0.34. The concomitant use of
dexamethasone might promote the development of lymphopenia
in some of the patients, but in general, we do not have sufficient
evidence to say it is associated with lymphopenia in this cohort.
Although one patient died of septic shock, both the chronic
use of steroids and the pancreatitis that preceded this event likely
contributed to her death. Interestingly, one patient who received
erlotinib at 160 mg/m2 developed a grade 3 increase in serum
lipase without radiologic findings suggestive of pancreatitis in the
phase I study (14). There is only one report of fatal pancreatitis
in a 46-year-old patient with non-small-cell lung cancer receiving
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erlotinib (23). However, in that case erlotinib was combined with
sunitinib, which is reported to cause grade 3 and 4 increases in
serum amylase and lipase in 5 and 16% of adult patients with
renal carcinoma, respectively (24).
Several studies in adults with GBM suggested that spe-
cific tumor markers are associated with a better response to
small-molecule inhibitors of EGFR, including erlotinib (13, 25).
Although a recent study showed a slightly higher occurrence of
EGFR amplification and/or mutations in children with HGG (26),
larger recent genome-wide molecular analyses demonstrated that
these changes occur in only a few cases (27, 28). Although we per-
formed extensive molecular analysis in the phase I study (14), we
did not perform these studies in the current trial because of the
poor outcome of patients. Likewise, a more recent randomized
clinical trial in adults with progressive GBM showed that erlotinib
less effective than temozolomide and lomustine (21).
In summary, similar to previous studies using other chemother-
apy regimens, we showed that the use of erlotinib during and
after local RT did not change the poor outcome of children with
intracranial AA and GBM. The advances made in elucidating the
molecular mechanisms regulating the genesis of pediatric HGG
(27–29) will hopefully lead to the use of targeted therapies that are
more suitable to the biologic characteristics of these cancers.
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